Retatrutide Dosing Protocols: Phase 2 Study Design, Escalation Schedules, and Preclinical Data

By Justin Cartier

For the wider context, see our overview of research peptides for weight loss.

Retatrutide is dosed once a week as a subcutaneous injection. The whole idea behind the schedule is patience. You start low at 2 mg. Then you step the dose up gradually toward a target of 4, 8, or 12 mg across roughly 16 weeks. That slow escalation isn’t an accident. It’s the single most reliable way to keep the stomach side effects like nausea from getting out of hand.^[1]

This article is for research and educational use only. Retatrutide is an experimental research compound. It isn’t approved for human use, and nothing here is medical advice.

The gentle climb comes from a lesson the whole GLP-1 field learned the hard way. Pushing the dosage up too quickly triggers nausea and vomiting severe enough to make people quit. Every dropout inflates the discontinuation rate. It also drags down the average weight reduction. So the Phase 2 retatrutide trial opened at 2 mg per week. It worked its way up in measured steps over sixteen weeks. That gave the gut enough time to adapt at each rung. As a result, nausea and vomiting stayed noticeably lower than they had been in the early semaglutide studies.

Here is what made the results so interesting. Weight loss increased at every single dose level, from the smallest 1 mg arm right up to the top group. There was no hint of the curve flattening out at the ceiling dose. That clean, orderly dose-response is exactly why the Phase 3 program is now testing whether there’s still headroom above the current maximum. For anyone running research, the takeaway on dosing strategy holds at whatever target you land on. Start low. Escalate slowly. Let tolerability rather than impatience set the pace.

This guide walks through the dose schedule itself and what the data show at each step. It compares retatrutide dosing against semaglutide and tirzepatide. It also covers how to reconstitute research material properly and what to do about a missed dose. Finally, it looks at what the Phase 3 plan hints about where this peptide is heading.

Typical retatrutide dosing schedule

The Phase 2 obesity trial ran a straightforward four-weeks-per-step ladder. Participants took 2 mg weekly under the skin for the first four weeks as the starting dose. They moved to 4 mg for weeks five through eight. They stepped up to 8 mg for weeks nine through twelve. Then they held at the 12 mg maintenance dose from week thirteen onward. The lower-dose arms simply stopped climbing earlier. They capped out at 4 mg or 8 mg while following the exact same rhythm.

The Phase 3 TRIUMPH program keeps that same four-week cadence. It spreads its target doses of 4, 8, and 12 mg across different treatment arms. Urva and colleagues, in The Lancet, characterised LY3437943 as a single peptide that activates the glucagon, GIP, and GLP-1 receptors. The whole escalation was engineered to keep the stomach side effects manageable while it works up to hitting all three of those targets at once.^[2]

What is the starting dose of retatrutide?

The starting dose is 2 mg once a week for the first four weeks. That deliberately low opening is there purely to keep the class-wide stomach side effects in check. Jumping straight in at something like 8 mg sharply spikes nausea, vomiting, and dropout. That is why every drug in this family ramps up slowly instead of launching at full strength. Think of the first month as letting the gut find its footing before the real dose increase begins.

How quickly can the retatrutide dose be increased?

The standard interval for each dose increase is every four weeks. Going faster than that tends to raise side effects without actually improving the final outcome. The receptor effects accumulate over weeks regardless of how quickly you turn the dial. A slower step of six to eight weeks is sometimes used for people with especially sensitive stomachs. Dedicated research protocols may run their own escalation schedules specifically to study how the drug behaves over time.

What is the maximum dose of retatrutide?

The highest dose tested in Phase 2 was 12 mg weekly. Phase 3 has held that same figure as its ceiling. Larger amounts in the 15 to 20 mg range were explored in earlier work. But they produced considerably more stomach upset without a matching bump in results. So the top dose settled where it did. In the current trials, that maintenance level looks like the genuine sweet spot where efficacy and tolerability meet.

How much retatrutide do you take?

For the standard obesity protocol you begin at 2 mg weekly. You then escalate over roughly twelve to sixteen weeks toward a target of 4, 8, or 12 mg, depending on which group you’re modelling. Research protocols generally cover that same 2 to 12 mg per week range delivered as a subcutaneous injection. Notably, the dosage isn’t scaled to body weight in the current trials. The receptor effects turn out to be fairly even across the whole obesity weight range. So per-kilogram adjustment isn’t needed.

How do you reconstitute retatrutide?

Research-grade retatrutide arrives as a lyophilized, or freeze-dried, powder, typically 10 mg or 15 mg per vial. It has to be reconstituted with bacteriostatic water before anything else happens. Take a 10 mg vial as the worked example. Adding 1.0 mL of bacteriostatic water yields a concentration of 10 mg/mL. That means a 0.4 mL draw pulls up 4 mg. Adding 2.0 mL instead yields 5 mg/mL. The same 4 mg then lives in a slightly larger 0.8 mL draw. The technique matters as much as the math here. Run the water slowly down the inside wall of the vial rather than blasting it straight onto the powder pellet. Then swirl the vial gently to dissolve everything instead of shaking it. Store the mixed solution in the fridge, where it stays stable for roughly 28 days. Insulin syringes on the U-100 scale are the tool of choice for accurate measuring. On that scale, 40 units simply corresponds to 0.4 mL.

What time of day should you take retatrutide?

The trials don’t pin down a specific time of day. The common-sense approach is simply to keep the timing consistent. Dose on the same day each week at roughly the same hour so levels stay even. Morning versus evening hasn’t been shown to change either results or side effects. Still, some people lean toward evening dosing for a practical reason. Nausea tends to peak a day or two after a dose. It can be partly slept through if the injection goes in at night.

What happens if you miss a dose of retatrutide?

Standard practice is fairly forgiving as long as you’re within 48 hours of the scheduled time. In that case, you just take the dose as soon as you remember. Once more than 48 hours have gone by, the better move is to skip that dose entirely. Rejoin the normal schedule rather than doubling up to compensate. One situation genuinely changes things. That is a long gap of more than two weeks since the last dose. It calls for restarting the escalation from a lower step. The stomach side effects come roaring back if you leap straight to a maintenance dose after that kind of break.

Retatrutide dose response

Weight loss climbs steadily with the dose in a way that’s unusually tidy. The Phase 2 obesity paper reported that retatrutide, activating the GIP, GLP-1, and glucagon receptors together, produced dose-dependent results. Weight loss over 48 weeks was about 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at the top dose.^[1] Tetelbaun and colleagues, in Cardiology in Review, likewise documented greater weight loss with retatrutide than placebo across every dose level. They also reported HbA1c drops of 1.5 to 2.0 points at the higher doses.^[3] More recent work adds to this. Coskun and colleagues, in The Lancet Diabetes & Endocrinology, showed the drug clearly improved metabolic health. It lowered total body fat mass in people with type 2 diabetes.^[4]

Retatrutide dosing vs other weight loss medications

Line the escalation schedules up side by side, and the differences within this drug class get easy to see. Semaglutide, sold as Wegovy, climbs through 0.25, 0.5, 1.0, 1.7, and finally 2.4 mg weekly. It takes about seventeen weeks to reach its top dose. Tirzepatide, sold as Zepbound, has the longest ramp of the three. It moves through 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly across roughly twenty weeks. Retatrutide gets there fastest. It runs 2, 4, 8, and 12 mg weekly over about sixteen weeks. All three share the same four-week interval between steps. But retatrutide reaches its ceiling sooner simply because it uses four steps rather than six. Its doubling jumps from 2 to 4 to 8 to 12 are bigger than tirzepatide’s gentler increments. That is what adds a little extra stomach burden during the escalation.

Common side effects and how to manage them

The main side effects are, predictably, stomach problems. Kaur and colleagues, in the European Journal of Clinical Pharmacology, describe retatrutide as a triple peptide that engages the glucagon receptor on top of GIP and GLP-1. Its side effects are led by the gastrointestinal symptoms common to the whole class.^[5] Managing them is mostly practical. For nausea, small frequent meals help, and so does steering clear of high-fat foods on dose days. Anti-nausea medication is reserved for the severe cases. Vomiting is handled by staying hydrated and holding or lowering the dose if it persists. Diarrhea and constipation respond to standard dietary steps. Injection-site reactions get easier if you rotate across the belly, thigh, and outer arm. One of the most useful tricks of all is the step-up pause. You simply stay at the current dose for an extra week or two whenever side effects are running high before climbing again. In Phase 2, somewhere between 6 and 16 percent of people stopped because of side effects depending on dose. That was slightly higher than tirzepatide at comparable dose steps.

Before you run an experiment, buy research peptides in Canada and confirm the certificate of analysis up front.

Legal status and sourcing

Retatrutide isn’t yet approved by Health Canada or the FDA, since the Phase 3 TRIUMPH program is still running. So research-grade material is sold as a research chemical for laboratory use only. The legal framework and supplier criteria for buying peptides in Canada lay out how that works.

Dosing accuracy depends on getting real material. So put a few plain questions to any supplier before you buy. Does the Certificate of Analysis (COA) come from an independent third-party lab, not the seller’s own bench? Is it tied to the exact batch or lot in your vial? Does it include the actual HPLC chromatogram with purity at 98 percent or higher? And does the mass spectrometry (MS) reading match retatrutide’s expected mass of about 4,731 Da (molecular formula C221H342N46O68)? For any live-animal or cell work, ask for endotoxin and sterility testing too. A vendor that answers all of these plainly is the one worth trusting.

Reviv Peptides supplies research-grade retatrutide with a third-party COA and HPLC purity confirmation. Researchers can order Retatrutide in Canada with verified documentation.

Retatrutide dosing questions

How much retatrutide do you take?

You start at 2 mg weekly. You then escalate over twelve to sixteen weeks toward a target of 4, 8, or 12 mg as a subcutaneous injection. The 12 mg maintenance dose delivers the most weight loss, at about 24.2 percent over 48 weeks.

How do you reconstitute retatrutide?

Add 1.0 mL or 2.0 mL of bacteriostatic water to a 10 mg vial. Adding 1.0 mL gives 10 mg/mL, and 2.0 mL gives 5 mg/mL. Swirl gently to dissolve and keep it refrigerated, where it stays stable for roughly 28 days. Use insulin U-100 syringes for accurate measuring.

What time of day should you take retatrutide?

The trials don’t set a time of day. Keeping the timing steady on the same day each week is what’s preferred. Evening dosing is sometimes chosen so you can sleep through the nausea peak that follows a dose.

What is the typical retatrutide dosing schedule?

It’s a weekly step-up running 2, then 4, then 8, then 12 mg. You hold each step for four weeks. After that, the target dose continues long-term. Going up faster than that just causes more stomach side effects.

What happens if you miss a dose of retatrutide?

If you’re within 48 hours of the scheduled time, take it when you remember. If more than 48 hours have passed, skip it and rejoin the normal schedule without doubling up. Note that any long gap of more than two weeks calls for restarting the escalation.

Key data point: in the Phase 2 dose-escalation study (Jastreboff and colleagues, 2023, NEJM), participants on the 12 mg schedule lost an average of 24.2 percent of body weight by week 48. Nearly everyone in that group lost at least 5 percent of their starting body weight.^[1]

Summary

Retatrutide dosing escalates every four weeks from a 2 mg start toward a target of 4, 8, or 12 mg. It is given once a week as a subcutaneous injection. The top dose delivered about 24.2 percent average weight loss over 48 weeks in the Phase 2 obesity trial. Reconstitution relies on bacteriostatic water in 1 to 2 mL amounts for the typical research vials. A missed dose can still be taken within 48 hours, while longer gaps call for restarting the escalation. The side effects stay stomach-heavy, with 6 to 16 percent of people stopping depending on dose. It isn’t yet approved. Research-grade material is legal in Canada and the United States for laboratory use only.

Sources: [1] Phase 2 obesity trial of retatrutide, PubMed. [2] LY3437943 triple agonist, phase 1b in type 2 diabetes, PubMed. [3] Retatrutide as the first triple agonist for anti-obesity, PubMed. [4] Retatrutide effects on body composition in type 2 diabetes, PubMed. [5] Retatrutide triple receptor agonist review, PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.